| Name | Title | Contact Details |
|---|
Our main practice areas include Employment Law, Intellectual Property Law, Wills, Trusts & Asset Protection, Business Law, and General Civil Litigation. We have been in business for over twenty years, and our stellar reputation is best reflected in our reviews.
Ingersoll Rand Inc. (NYSE:IR), driven by an entrepreneurial spirit and ownership mindset, is dedicated to Making Life Better for our employees, customers, shareholders, and planet. Customers lean on us for exceptional performance and durability in mission-critical flow creation and industrial solutions. Supported by over 80+ respected brands, our products and services excel in the most complex and harsh conditions. Our employees develop customers for life through their daily commitment to expertise, productivity, and efficiency. For more information, visit www.IRCO.com.
Handcrafted outdoor furniture with over 20 years of DEDON experience. As a manufacturer of exclusive outdoor furniture, DEDON is one of the worlds leading providers in this industry and has received numerous international design awards. The company, which was founded in 1990 by the former professional soccer player Bobby Dekeyser, revolutionized the outdoor furniture market with its groundbreaking designs within only a few years. The basis for DEDONs success is a highly durable synthetic fiber manufactured at the headquarters in the North of Germany. Developed over 20 years ago, the unique DEDON fiber still is considered "the original" in the industry; the "Made by DEDON" seal stands for the highest standards of quality and design. DEDON furniture is designed by international designers, matches German quality standards in terms of production, and is manufactured by hand in a traditional fashion by braiding artisans on the island of Cebu in the Philippines. Every piece of DEDON furniture embodies the combination of modern technology and century-old craftsmanship.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
The Siegfried Group is a Philadelphia, PA-based company in the Business Services sector.